Table 1.
132 ChIP-seq datasets of human wild-type p53 published using multiple cell lines cultured with various conditions
| Cells | Treatment | public accession | Reference |
|---|---|---|---|
| A498 | IR (4 Gy, 2 h) | GSM2677375 | (52) |
| A549 | IR (4 Gy, 2 h) | GSM2677380 | (52) |
| A549 | Nutlin (5 μM, 2 h) | GSM3771330 | (52) |
| A549 | Nutlin (5 μM, 2 h) | GSM3771331 | (52) |
| A549 | TGFβ (2.5 ng/ml, 5 days) + Nutlin (5 μM, 2 h) | GSM3771332 | (52) |
| A549 | TGFβ (2.5 ng/ml, 5 days) + Nutlin (5 μM, 2 h) | GSM3771333 | (52) |
| A2780 | Cisp (2 μM, 3 days) | GSM3720408 | (53) |
| A2780 | vehicle | GSM3720407 | (53) |
| BJ | IR (10 Gy, 6 h) | GSM1348340 | (54) |
| BJ | RasV12+control vector | GSM508793 | (55) |
| BJ | untreated | GSM1348339 | (54) |
| CAL51 | IR (5 Gy, 1 h) | ERR375899 | (56) |
| CAL51 | IR (5 Gy, 2 h) | ERR375900 | (56) |
| CAL51 | untreated | ERR375898 | (56) |
| Calu-1 | DMSO (0.01%, 48 h) | GSM3682106 | (57) |
| Calu-1 | Belinostat (0.1 μM, 48 h) + Cisp (10 μM, 48 h) | GSM3682107 | (57) |
| FSF | DXR (0.2 μg/ml, 12 h) | GSM1342488 | (47) |
| FSF | DXR (0.2 μg/ml, 12 h) | GSM1342494 | (47) |
| GM06993 + GM11992 | DXR (0.5 μM, 18 h) | GSM1142696 | (58) |
| GM06993 + GM11992 | untreated | GSM1142697 | (58) |
| GM12878 | IR (10 Gy, 4 h) | GSM1142702 | (58) |
| GM12878 | Nutlin (10 μM, 18 h) | GSM1142700 | (58) |
| H460 | IR (4 Gy, 2 h) | GSM2677379 | (52) |
| HCT116 | 5-FU (350 μM, 12 h) | GSM1412744 | (59) |
| HCT116 | 5-FU (350 μM, 6 h) | SRR1343581 | (60) |
| HCT116 | 5-FU (375 μM, 6 h) | GSM1417250 | (61) |
| HCT116 | 5-FU (50 μg/ml, 24 h) | - | (62) |
| HCT116 | Camptothecin (CPT) (1.5 μM, 4h) | SRR2817469 | (63) |
| HCT116 | Camptothecin (CPT) (5 μM, 8 h) | SRR2967009,SRR2967010 | (64) |
| HCT116 | DMSO (0.05%) control | SRR1343582 | (60) |
| HCT116 | DMSO (0.2%, 12 h) | SRR4090090 | (9) |
| HCT116 | DMSO (4 h) | SRR2817470 | (63) |
| HCT116 | DXR (1.6 μM, 6 h) | SRR1343583 | (60) |
| HCT116 | IR (4Gy, 2 h) | GSM2677381 | (52) |
| HCT116 | IR (8 h) | SRR1539836 | (65) |
| HCT116 | IR (8 h) | SRR1539837 | (65) |
| HCT116 | Negative control siRNA (3 days) | GSM3103907 | (66) |
| HCT116 | Nutlin (10 μM, 6 h) | SRR1343584 | (60) |
| HCT116 | Nutlin (10 μM, 12 h) | SRR4090091 | (9) |
| HCT116 | Nutlin (12 h) | GSM3103906 | (66) |
| HCT116 | siRNA against iASSP (3 days) | GSM3103908 | (66) |
| HCT116 | Untreated | GSM1412743 | (59) |
| HCT116 | Untreated | SRR1539838 | (65) |
| HCT116 | Untreated | SRR2967011,SRR2967012 | (64) |
| HCT116 | Untreated | GSM3103905 | (66) |
| HDF | DMSO (48 h) | SRR3125899 | (67) |
| HDF | Nutlin (10 μM, 48 h) | SRR3125901 | (67) |
| HepG2 | control AdV (48 h) + UVC (24 h) | GSM1581946 | (68) |
| HepG2 | Hepatitis B (HBx)-expressing AdV (48 h) + UVC (24 h) | GSM1581947 | (68) |
| hESC | DXR (6 h) | GSM981236 | (51) |
| hESC | RA (1 μM, 48 h) | GSM981237 | (51) |
| hESC | Untreated | GSM981235 | (51) |
| HFK | Cisp (25 μM, 24 h) | GSM1366691,GSM1366697 | (12) |
| HFK | DXR (350 nM, 24 h) | GSM1366690,GSM1366696 | (12) |
| HFK | Untreated | GSM1366689,GSM1366695 | (12) |
| HuSkFib | Nutlin (5 μM, 6 h) | GSM3020116, GSM3378524 | (48) |
| HuSkFib | DMSO (6 h) | GSM3020115, GSM3378522 | (48) |
| IMR90 | 5-FU (375 μM, 6 h) | GSM783262 | (69) |
| IMR90 | DMSO control | GSM1418969 | (25) |
| IMR90 | Etop (100 μM, 6 h) | SRR7357223 | (70) |
| IMR90 | Etop (100 μM, 24 h) | GSM1294880,GSM1294881,GSM1294893,GSM1294882,GSM1294883 | (71) |
| IMR90 | Nutlin (5 μM, 6 h) | GSM1418970 | (25) |
| IMR90 | O/E E1A/RasG12V | GSM1294879,GSM1294885,GSM1294891 | (71) |
| IMR90 | O/E RasG12V | GSM1294877,GSM1294878,GSM1294890 | (71) |
| IMR90 | Senescent (HRasV12) | GSM1048851 | (72) |
| IMR90 | Untreated | GSM1294876,GSM1294884 | (71) |
| IMR90 | Untreated | GSM1048850 | (72) |
| LOXIMVI | IR (4 Gy, 2 h) | GSM2677373 | (52) |
| Lymphocyte_BS104 | DMSO (0.1%, 24 h) | GSM2988942 | (6) |
| Lymphocyte_BS104 | DXR (0.3 μg/ml, 24 h) | GSM2988944 | (6) |
| Lymphocyte_BS104 | Nutlin (10 μM, 24 h) | GSM2988946 | (6) |
| Lymphocyte_BS116 | DMSO (0.1%, 24 h) | GSM2988948 | (6) |
| Lymphocyte_BS116 | DXR (0.3 μg/ml, 24 h) | GSM2988950 | (6) |
| Lymphocyte_BS116 | Nutlin (10 μM, 24 h) | GSM2988952 | (6) |
| Lymphocyte_BS45 | DMSO (0.1%, 24 h) | GSM2988930 | (6) |
| Lymphocyte_BS45 | DXR (0.3 μg/ml, 24 h) | GSM2988932 | (6) |
| Lymphocyte_BS45 | Nutlin (10 μM, 24 h) | GSM2988934 | (6) |
| Lymphocyte_BS90 | DMSO (0.1%, 24 h) | GSM2988936 | (6) |
| Lymphocyte_BS90 | DXR (0.3 μg/ml, 24 h) | GSM2988938 | (6) |
| Lymphocyte_BS90 | Nutlin (10 μM, 24 h) | GSM2988940 | (6) |
| MALME3 | IR (4 Gy, 2 h) | GSM2677378 | (52) |
| MCF7 | 5-FU (100 μM, 8 h) | SRR287799 | (73) |
| MCF7 | Decitabine (2 μM, 5 days) | GSM2740046 | (52) |
| MCF7 | DMSO (0.2%, 12 h) | SRR4090093 | (9) |
| MCF7 | IR (4 Gy, 2 h) | GSM2677372 | (52) |
| MCF7 | IR (10 Gy, 1 h) | SRR5690016 | (74) |
| MCF7 | IR (10 Gy, 2.5 h) | SRR5690017 | (74) |
| MCF7 | IR (10 Gy, 4 h) | SRR5690018 | (74) |
| MCF7 | IR (10 Gy, 5 h) | SRR5690019 | (74) |
| MCF7 | IR (10 Gy, 7.5 h) | SRR5690020 | (74) |
| MCF7 | IR (10 Gy, 7.5 h), then sequential Nutlin | SRR5690021 | (74) |
| MCF7 | neocarzinostatin (NCZ) (400 ng/ml, 3 h) | SRR5857009,SRR5857012 | (75) |
| MCF7 | Nutlin (5 μM, 2 h) | GSM2677384 | (52) |
| MCF7 | Nutlin (5 μM, 24 h) | GSM1146168 | (76) |
| MCF7 | Nutlin (10 μM, 8 h) | SRR287800 | (73) |
| MCF7 | Nutlin (10 μM, 12 h) | SRR4090094 | (9) |
| MCF7 | RITA (0.1 μM, 8 h) | SRR287797 | (73) |
| MCF7 | RITA (1 μM, 8 h) | SRR287798 | (73) |
| MCF7 | Untreated | SRR287796 | (73) |
| MCF7 | Untreated | SRR5690015 | (74) |
| MCF7 | Untreated | SRR5857010,SRR5857013 | (75) |
| MCF7 | Untreated | GSM2740045 | (52) |
| MCF7 | Untreated | GSM1429753 | (77) |
| MCF10A | Nutlin (5 μM, 6 h) | GSM3020136, GSM3378513 | (48) |
| MCF10A | DMSO (6 h) | GSM3020135, GSM3378510 | (48) |
| MDA-MB-175VII | Untreated | GSM1429754 | (77) |
| PBMC | 5-FU (50 μg/ml, 24 h) | - | (62) |
| SaOS-2 | O/E GFP | ERR206782,ERR206794,ERR206795 | (11) |
| SaOS-2 | O/E p53-wt (18 h) | ERR206781,ERR206779,ERR206784 | (11) |
| SaOS-2 | O/E p53-wt (24 h) | GSM501691,GSM501692 | (78) |
| SaOS-2 | O/E p53-wt (24 h) | GSM1241481 | (79) |
| SJSA | DMSO (0.2%, 12 h) | SRR4090096 | (9) |
| SJSA | Nutlin (10 μM, 12 h) | SRR4090097 | (9) |
| SKMEL5 | IR (4 Gy, 2 h) | GSM2677377 | (52) |
| SW480 | Empty vector | SRR1920910 | (80) |
| SW480 | p53 wt O/E | SRR1920909 | (80) |
| UACC62 | IR (4 Gy, 2 h) | GSM2677382 | (52) |
| UACC257 | IR (4 Gy, 2 h) | GSM2677383 | (52) |
| UACC257 | Nutlin (5 μM, 2 h) | GSM2677385 | (52) |
| U2OS | ActD (5 nM, 24 h) | GSM545807 | (81) |
| U2OS | DMSO (0.1%, 24 h) control | GSM1133482 | (82) |
| U2OS | DXR (0.6 μg/ml, 24 h) | GSM1133484 | (82) |
| U2OS | Etop (10 μM, 24 h) | GSM545808 | (81) |
| U2OS | IR (4 Gy, 2 h) | GSM2677376 | (52) |
| U2OS | Nutlin (10 μM, 24 h) | GSM1133486 | (82) |
| U2OS | Untreated | SRR1344509,SRR1343579 | (60) |
| U2OS | Untreated | GSM1133488 | (82) |
| U2OS | Untreated | ERR359700,ERR359705 | (83) |
| U2OS | UV (50 J, 6 h) | SRR1344510,SRR1343580 | (60) |
| U2OS | UVC (20 J/m2, 16 h) | ERR359704,ERR359706 | (83) |
| U2OS | UVC (20 J/m2, 8 h) | ERR359699,ERR359702 | (83) |
| UO31 | IR (4 Gy, 2 h) | GSM2677374 | (52) |
Abbreviations: 5-FU, 5-fluorouracil; ActD, actomycin D; Cisp, cisplatin; DXR, doxorubicin; Etop, etoposide; IR, ionizing radiation; nutlin, Nutlin-3; RITA, reactivation of p53 and induction of tumor cell apoptosis; UV, ultraviolet radiation; p53 O/E, p53 overexpression; RA, retinoic acid; Ras O/E, Ras overexpression; DMSO, dimethyl sulfoxide; TGFβ, Transforming growth factor beta; AdV, adenovirus.